Pharmaceutical News

RSS

SGS announces total package testing solution for medical device, pharma product manufacturers

SGS Consumer Testing Services today announced an expansion of its package testing services with a global program to ensure packaging integrity for medical devices and pharmaceutical products. The program – announced at this week's EastPack 2010 conference in New York - offers one-stop testing of product containers, secondary packaging and transit packaging to evaluate the product protection capabilities, durability and environmental sustainability of all package components.

10 Jun 2010

Ontario Pharmacists' Association disappointed with government's regulatory changes

The Ontario Pharmacists' Association today expressed concerns and disappointment with the Ontario government's announcement that it is moving ahead with regulatory changes that will significantly reduce support to Ontario pharmacists and their patients.

10 Jun 2010

Study: ChEI improves driving skills in patients with mild AD

A promising study from Rhode Island Hospital demonstrated that cholinesterase inhibitors, a type of medication often prescribed for Alzheimer's disease, improved some cognitive skills in patients with mild AD - skills that are necessary for driving. Findings from the study showed that after being treated with a ChEI, AD patients improved in some computerized tests of executive function and visual attention, including a simulated driving task.

10 Jun 2010

NICE decides not to recommend lapatinib for women with advanced breast cancer

The National Institute for Health and Clinical Excellence has decided not to recommend the oral drug lapatinib (Tyverb) for women with advanced breast cancer, except for use in clinical trials.

10 Jun 2010

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

Roxane Laboratories, Inc. announced today the Abbreviated New Drug Application (ANDA) approval of Valacyclovir Hydrochloride Tablets 500mg and

10 Jun 2010

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Intellect Neurosciences, Inc announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders.

9 Jun 2010

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Northwest Biotherapeutics, Inc., developer of the DCVax personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group.

9 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Impax reaches agreement with Endo and Penwest to settle pending litigation for OPANA ER

Impax Laboratories, Inc. today announced that it has reached agreement with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle pending U.S. litigation with regard to the production and sale of generic formulations of OPANA ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

The Society of Gynecologic Oncologists has published its third in a series of four papers on a variety of cervical cancer issues and topics featured at "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare" Forum. The paper, entitled "Can the Barriers to HPV Vaccination in High-Risk Populations be Overcome?" appears in the June, 2010 issue of Gynecologic Oncology Journal.

9 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Emerson Ecologics announces exclusive distribution of EcoNugenics' BreastDefend dietary supplement

Emerson Ecologics, LLC announces an exclusive distribution to healthcare practitioners of BreastDefend™, EcoNugenics' newest product. BreastDefend is a professional dietary supplement formulated specifically to promote and maintain breast cellular health. EcoNugenics chose to distribute this product solely through Emerson Ecologics for the initial product launch because of Emerson's 16,000 practitioner customer base, as well as their strong quality assurance program.

9 Jun 2010

Drugs in R&D journal transformed from fee-based access to OA

The Adis journal Drugs in R&D has been transformed from fee-based access to open access, according to its parent company Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to professionals in the pharmaceutical and biotech fields.

9 Jun 2010

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

Ontario's Community Pharmacies Coalition reacts to new regulations and vows to fight for patient care

Ontario's Community Pharmacies Coalition are extremely disappointed by yesterday's announcement by Health Minister Deb Matthews and the posting of amendments to regulations under the OBDA and DIDFA as it all but assures that Ontario patients will be less able to freely access the front-line community healthcare they have come to rely on.

9 Jun 2010

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

The Melanoma Network of Canada is excited with the new hope that long-anticipated results of a late-stage skin cancer trial brings to patients with advanced melanoma. The results, presented at the American Society of Clinical Oncology annual meeting, show increased survival with the experimental treatment ipilimumab in patients with previously-treated metastatic melanoma, the most deadly form of skin cancer.

9 Jun 2010

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

9 Jun 2010

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Inc and Forest Laboratories, Inc., today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

9 Jun 2010

Pharmaceutical News

SGS announces total package testing solution for medical device, pharma product manufacturers

Ontario Pharmacists' Association disappointed with government's regulatory changes

Study: ChEI improves driving skills in patients with mild AD

NICE decides not to recommend lapatinib for women with advanced breast cancer

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Some commonly used drugs cause bone loss: New research

Impax reaches agreement with Endo and Penwest to settle pending litigation for OPANA ER

Multiple presentations on nab-driven chemotherapy at 46th ASCO

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Emerson Ecologics announces exclusive distribution of EcoNugenics' BreastDefend dietary supplement

Drugs in R&D journal transformed from fee-based access to OA

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

Blood vessel-blocking drug slows prostate cancer progression: Experts

Ontario's Community Pharmacies Coalition reacts to new regulations and vows to fight for patient care

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News